Novel compounds in the treatment of lung cancer: current and developing therapeutic agents

References

• American Cancer Society: Cancer Facts and Figures 2010Atlanta, GAAmerican Cancer Society2010
   Google Scholar
• HerbstRSHeymachJVLippmanSMMolecular origins of cancer: lung cancerN Engl J Med20083591367138018815398
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNational Comprehensive Cancer Network Guidelines V. 2009 www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
   Google Scholar
• AzzoliCGBakerSTeminSAmerican Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancerJ Clin Oncol2009276251626619917871
   PubMed Web of Science ®Google Scholar
• GossageLMadhusudanSCurrent status of excision repair cross complementing-group 1 (ERCC1) in cancerCancer Treat Rev20073356557717707593
   PubMed Web of Science ®Google Scholar
• RyuJSHongYCHanHSAssociation between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapyLung Cancer20044431131615140544
   PubMed Web of Science ®Google Scholar
• HolmBMellemgaardASkovTSkovBGDifferent impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabineJ Clin Oncol2009274254425919667277
   PubMed Web of Science ®Google Scholar
• LordRVBrabenderJGandaraDLow ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancerClin Cancer Res200282286229112114432
   PubMed Web of Science ®Google Scholar
• BootonRWardTAshcroftLERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small-cell lung cancerJ Thorac Oncol2007290290617909351
   PubMed Web of Science ®Google Scholar
• EdelmanMartin J MD. Novel cytotoxic agents for non-small cell lung cancerJ Thorac Oncol2006175275517409954
   PubMed Web of Science ®Google Scholar
• FrancisPAKrisMGRigasJRGrantSCMillerVAPaclitaxel (Taxol) and docetaxel (Taxotere): Active chemotherapeutic agents in lung cancerLung Cancer199512Suppl 1S163S1727551925
   PubMed Web of Science ®Google Scholar
• GrantDSWilliamsTLZahaczewskyMDickerAPComparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)Int J Cancer200310412112912532428
   PubMed Web of Science ®Google Scholar
• RansonMDavidsonNNicolsonMRandomized trials of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancerJ Natl Cancer Inst2000921074108010880550
   PubMed Web of Science ®Google Scholar
• CernyTKaplanSPavlidisNDocetaxel (Taxotere) is active in non-small cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)Br J Cancer1994703843877914429
   PubMed Web of Science ®Google Scholar
• BonoIPKimKFaircloughDComparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cispaltin versus etoposide with cisplatin: results of the Eastern Cooperative Oncology Group trialJ Clin Oncol20001862363110653877
   PubMed Web of Science ®Google Scholar
• SingerJWBakerBDe VriesPPoly-(L)-glutamic acid-paclitaxel (CT-2103)[XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical dataAdv Exp Med Biol2003519819912675210
   PubMed Web of Science ®Google Scholar
• BonomiPPaz-AresLLangerCXYOTAX TM vs. docetaxel for the second-line treatment of non-small cell lung cancer: the STELLAR 2 phase III studyLung Cancer200549S35
   Web of Science ®Google Scholar
• LangerCJSocinskiMAO’ByrneKJPaclitaxel poliglumex (PPX)/carboplatin vs. paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naive advanced non-small cell lung cancer: a phase III studyProc Am Soc Clin Oncol200623623s
   Google Scholar
• DesaiNTrieuVYaoZIncreased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxelClin Cancer Res2006121317132416489089
   PubMed Web of Science ®Google Scholar
• RubinEHRothermelJTesfayeFDose-finding study of weekly single-agent patupilone in patients with advanced solid tumorsJ Clin Oncol2006239120912916301595
   PubMed Web of Science ®Google Scholar
• ManiSMcDaidHHamiltonAPhase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumorsClin Cancer Res2004101289129814977827
   PubMed Web of Science ®Google Scholar
• YeeLLynchTVillalona-CaleroMA phase II study of KOS-862 (epothilone D) as second line therapy in non-small cell lung cancer. Abstract]Proc Am Soc Clin Oncol200623652s
   Web of Science ®Google Scholar
• EdelmanMJBretonJLSandlerARandomized phase II study of epothilone analog BMS-247550 in patients with non-small cell lung cancer who have failed first line platinum based chemotherapyLung Cancer200341S5
   Google Scholar
• YeeKWHageyAVerstovsekSPhase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignanciesClin Cancer Res2006116615662416166440
   PubMed Web of Science ®Google Scholar
• ElledgeSJZhouZAllenJBRibonucleotide reductase: regulation, regulation, regulationTrends Biochem Sci1992171191231412696
   PubMed Web of Science ®Google Scholar
• BeplerGKusmartsevaISharmaSRRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancerJ Clin Oncol2006244731473716966686
   PubMed Web of Science ®Google Scholar
• DavidsonJDMaLFlagellaMAn increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell linesCancer Res2004643761376615172981
   PubMed Web of Science ®Google Scholar
• RosellRDanenbergKAlberolaVRibonucleotide reductase mRNA expression and survival in gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patientsClin Cancer Res2004101318132514977831
   PubMed Web of Science ®Google Scholar
• ReynoldsCObasajuCMichaelJRandomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancerJ Clin Oncol2009275808581519884554
   PubMed Web of Science ®Google Scholar
• CiuleanuTEBrodowiczTBelaniCPMaintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III studyJ Clin Oncol200826Suppl 15S426
   Web of Science ®Google Scholar
• ScagliottiGVParikhPvon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol2008263543355118506025
   PubMed Web of Science ®Google Scholar
• FidiasPMDakhilSRLyssAPPhase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancerJ Clin Oncol20092759159819075278
   PubMed Web of Science ®Google Scholar
• CiuleanuTBrodowiczTZielinskiCMaintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyLancet20093741432144019767093
   PubMed Web of Science ®Google Scholar
• MendelsohnJBaselgaJStatus of epidermal growth factor receptor antagonists in the biology and treatment of cancerJ Clin Oncol2003212787279912860957
   PubMed Web of Science ®Google Scholar
• LynchTJBellDHaberDCorrelation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trialsProc Am Soc J Clin Oncol200523Suppl 16S622 (abstract 7006).
   Web of Science ®Google Scholar
• CohenMHWilliamsGASridharaRUnited States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tabletsClin Cancer Res2004101212121814977817
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet20053661527153716257339
   PubMed Web of Science ®Google Scholar
• YangCHFukuokaMokTSFinal overall survival (OS) results from a phase 3, randomized, open-label, first-line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSLC) in Asia (IPASS)Program and abstracts of the 35th European Society of Medical Oncologists (ESMO) Congress2010 October 8–12Milan, Italy Abstract LBA212
   Google Scholar
• TsaoMSSakuradaACutzJCErlotinib in lung cancer – molecular and clinical predictors of outcomeN Engl J Med200535313314416014883
   PubMed Web of Science ®Google Scholar
• ShepherdFAPereiraJRCiuleanuTErlotinibin previously treated non-small-cell lung cancerN Engl J Med200535312313216014882
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLSATURN: Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicenter, randomized placebo-controlled phase 3 studyLancet Oncol20101152152920493771
   PubMed Web of Science ®Google Scholar
• PaoWMillerVZakowskiMEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci U S A2004101133061331115329413
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med200936195896719692684
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trialLancet Oncol20101112112820022809
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGEfficacy results from the randomized phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutationsProgram and abstracts of the 35th European Society of Medical Oncologists (ESMO) Congress2010 October 8–12Milan, Italy Abstract LBA13
   Google Scholar
• JännePAWangXFSocinskietMARandomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406J Clin Oncol201028Suppl 15 abstract 7503
   Google Scholar
• KwakELSordellaRBellDWIrreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProc Natl Acad Sci U S A20051027665767015897464
   PubMed Web of Science ®Google Scholar
• SequistLVBesseBLynchTJNeratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer20102830763083
   Google Scholar
• ZhouWErcanDChenLNovel mutant-selective EGFR kinase inhibitors against EGFR T790MNature20094621070107420033049
   PubMed Web of Science ®Google Scholar
• BaoRLaiCQuHCUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacological properties for cancer therapyClin Cancer Res2009154046405719509149
   PubMed Web of Science ®Google Scholar
• BaoRLaiCWDTargeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small-cell lung cancerMol Cancer Ther200983296330619952121
   PubMed Web of Science ®Google Scholar
• ShimamuraTLowellAMEngelmanJAShapiroGIEpidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycinsCancer Res2005646401640816024644
   PubMed Web of Science ®Google Scholar
• GeJNormantEPorterJPDesign, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygel danamycin as potent, water-soluble inhibitors of Hsp90J Med Chem2006494606461516854066
   PubMed Web of Science ®Google Scholar
• LaiCBaoRTaoXCUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activityCancer Res2010703647365620388807
   PubMed Web of Science ®Google Scholar
• CaiXZhaiHXWangJDiscovery of (7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide)(CUDC-101) as a potent multi-acting HDAC, EGFR and HER2 inhibitor for the treatment of cancerJ Med Chem2010532000200920143778
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced NSCLC (FLEX): an open-label randomised phase III trialLancet20093731525153119410716
   PubMed Web of Science ®Google Scholar
• CutsemEVKohneC-HHitreECetuximab and chemotherapy as initial treatment for metastatic colorectal cancerN Engl J Med20093601408141719339720
   PubMed Web of Science ®Google Scholar
• Khambata-FordSHarbisonCTHartLLAnalysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancerJ Clin Oncol20102891892720100958
   PubMed Web of Science ®Google Scholar
• BonnerJHarariPGiraltJRadiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J Med200635456757816467544
   PubMed Web of Science ®Google Scholar
• FolkmanJEndothelial cells and angiogenic growth factors in cancer growth and metastasis. IntroductionCancer Metastasis Rev199091711741705485
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med20063552542255017167137
   PubMed Web of Science ®Google Scholar
• MartinRJoachimVPPetrZBO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): C1-06J Thorac Oncol20072S360S361
   Web of Science ®Google Scholar
• DahlbergSESandlerABBrahmerJRClinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599J Clin Oncol20102894995420085937
   PubMed Web of Science ®Google Scholar
• MendelDBLairdADXinXIn vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipClin Cancer Res2003932733712538485
   PubMed Web of Science ®Google Scholar
• NovelloSSeagliottiGVRosellRPhase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancerBr J Cancer20091011543154819826424
   PubMed Web of Science ®Google Scholar
• ChuTFRupnickMAKerkelaRCardiotoxicity associated with tyrosine kinase inhibitor sunitinibLancet20073702011201918083403
   PubMed Web of Science ®Google Scholar
• GovindanRKrazakowskiMSzczesnaASunitinib in combination with erlotinib for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC): a phase III study CTS 2010Chicago Multidisciplinary Symposium in Thoracic Oncology2010 December 9–11Chicago Abstract LBPL2
   Google Scholar
• WilhelmSMAdnaneLNewellPVillanuevaALlovetJMLynchMPreclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalingMol Cancer Ther200873129314018852116
   PubMed Web of Science ®Google Scholar
• ScagliottiGvon PawelJReckMSorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): interim analysis (IA) results from the phase III, randomized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sorafenib, Carboplatin, and Paclitaxel Efficacy in NSCLC) Trial1st European Lung Cancer ConferenceApril 24–26, 2008Geneva, Switzerland Abstract 6
   Google Scholar
• BlumenscheinGJrSorafenib in lung cancer: clinical developments and future directionsJ Thorac Oncol200836 Suppl 2S124S12718520294
   PubMed Web of Science ®Google Scholar
• MorabitoAPiccirilloMCCostanzoRVandetanib: an overview of its clinical development in NSCLC and other tumorsDrugs Today (Barc)20104668369820967300
   PubMed Web of Science ®Google Scholar
• HerbstRSSunYEberhardtWEVandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialLancet Oncol20101161962620570559
   PubMed Web of Science ®Google Scholar
• De BoerRVansteenkisteJHumbletYVandetanib with pemetrexed in patients with previously treated non-small cell lung cancer (NSCLC): an open-label, multicenter phase I studyJ Clin Oncol200725Suppl 18 abstract 7654
   Web of Science ®Google Scholar
• NataleRBThongprasertSGrecoFAVandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST)J Clin Oncol200927Suppl 15 abstract 8009
   Web of Science ®Google Scholar
• LeeJHirshVParkKVandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized, double-blind phase III trial (ZEPHYR)J Clin Oncol201028Suppl 15 abstract 7525
   Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature200744856156617625570
   PubMed Web of Science ®Google Scholar
• MartelliMPSozziGHernandezLEML4-ALK rearrangement in non-small-cell lung tissuesAm J Pathol200917466167019147828
   PubMed Web of Science ®Google Scholar
• ShawATYeapBYMino-KenudsonMClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKJ Clin Oncol2009274247425319667264
   PubMed Web of Science ®Google Scholar
• ChoiYLTakeuchiKSodaMIdentification of novel isoforms of the EML4-ALK transforming gene in non-small-cell lung cancerCancer Res2008684971497618593892
   PubMed Web of Science ®Google Scholar
• WongDWLeungELSoKKThe EML4-ALK fusion gene is involved in various histologic types of lung cancers from non-smokers with wild-type EGFR and KRASCancer Res200811517231733
   Google Scholar
• ZhouHYLiQLeeJHAn orally available small-molecule inhibitor of c-met, PF-02341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsCancer Res2007674408441717483355
   PubMed Web of Science ®Google Scholar
• ChristensenJGZouHYArangoMECytoreductive antitumor activity of PF-02341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaMol Cancer Ther200763314332218089725
   PubMed Web of Science ®Google Scholar
• KwakELCamidgeDRClarkJClinical activity observed in phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066J Clin Oncol200927Suppl 15 abstract 3509
   Web of Science ®Google Scholar
• LiYYeXLiuJZhaJPeiLEvaluation of EML4-ALK fusion proteins in non-small-cell lung cancer using small molecule inhibitorsNeoplasia20111311121245935
   PubMed Web of Science ®Google Scholar
• BatusMFidlerMJBasuSFrequency of insulin-like growth factor 1 (IGFR-1) expression and correlation with clinical and selected molecular parameters in advanced non-small-cell lung cancer (NSCLC) patientsJ Clin Oncol20082622080
   Web of Science ®Google Scholar
• OubanAMuracaPYeatmanTCoppolaDExpression and distribution of insulin-like growth factor-1 receptor in human carcinomasHum Pathol20033480380814506643
   PubMed Web of Science ®Google Scholar
• WernerHLe RoithDNew concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasiaCell Mol Life Sci20005793294210950308
   PubMed Web of Science ®Google Scholar
• KarpDDPaz-AresLGNovelloSPhase II study of the anti-insulin-like growth factor type I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously treated, locally advanced or metastatic non-small-cell lung cancerJ Clin Oncol2009272516252219380445
   PubMed Web of Science ®Google Scholar
• HanJYChoiBGChoiJYLeeSYJuSYThe prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancerLung Cancer20065422723416935391
   PubMed Web of Science ®Google Scholar
• HewishMChauICunninghamDInsulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicineRecent Pat Anticancer Drug Discov20094547219149688
   PubMed Web of Science ®Google Scholar
• CiprianiNAAbidoyeOOVokesESalgiaRMET as a target for treatment of chest tumorsLung Cancer20096316917918672314
   PubMed Web of Science ®Google Scholar
• EderJPWoudeFVBoernerSCBoernerSALoRussoPMNovel therapeutic inhibitors of the c-Met signaling pathway in cancerClin Cancer Res2009152207221419318488
   PubMed Web of Science ®Google Scholar
• BeanJBrennanCShihJYMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProc Natl Acad Sci U S A20076104209322093718093943
   PubMed Web of Science ®Google Scholar
• PuriNSalgiaRSyngergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancerJ Carcinog200871818631381
   PubMedGoogle Scholar
• KwakELCamidgeDRClarkJClinical activity observed in a phase I dose-escalation trial of an oral MET and ALK inhibitor, PF-02341066J Clin Oncol200927Suppl 15 abstract 2509
   Web of Science ®Google Scholar
• ShawRICartleyLCRas, PI(3)K and mTOR signaling controls tumour growthNature200644142443016724053
   PubMed Web of Science ®Google Scholar
• YamamotoHShigematsuHNomuraMPIK3CA mutations and copy number gains in human lung cancersCancer Res2008686913392118757405
   PubMed Web of Science ®Google Scholar
• WestKALinnoilaIRBelinskySAHarrisCCDennisPATobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3′-kinase/Akt pathway in vitro and in vivoCancer Res20046444645114744754
   PubMed Web of Science ®Google Scholar
• LiuPChengHRobertsTMZhaoJJTargeting the phosphoinositide 3-kinase pathway in cancerNat Rev Drug Discov2009862764419644473
   PubMed Web of Science ®Google Scholar
• O’DonnelAFaivreSBurrisHAPhase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumorsJ Clin Oncol2008261588159518332470
   PubMed Web of Science ®Google Scholar
• PapadimitraikopoulouVSoriaJCDouillardJYA phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-1)J Clin Oncol200725Suppl 18 abstract 7589
   Web of Science ®Google Scholar
• PandyaKJLevyDEHidalgoMA randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy: a preliminary reportJ Clin Oncol200523Suppl 16 abstract 7005
   Web of Science ®Google Scholar
• MiltonDTRielyGJAzzoliCGPhase 1 trial of everolimus and gefitinib in patients with advanced non-small cell lung cancerCancer200711059960517577220
   PubMed Web of Science ®Google Scholar
• KhuriFRHarveyDSabaNFEverolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: a phase I studyJ Clin Oncol200927Suppl 15S421
   Web of Science ®Google Scholar
• MitaMMMitaACChuQSPhase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignanciesJ Clin Oncol20082636136718202410
   PubMed Web of Science ®Google Scholar
• PaoWWangTYRielyGJKRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibPLoS Med20052e1715696205
   PubMed Web of Science ®Google Scholar
• MarksJLBroderickSZhouQPrognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinomaJ Thorac Oncol2008311111618303429
   PubMed Web of Science ®Google Scholar
• RielyGJKrisMGRosenbaumDFrequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinomaClin Cancer Res2008145731573418794081
   PubMed Web of Science ®Google Scholar
• JasinskiPZwolakPTeraiKDudekANovel Ras pathway inhibition induces apoptosis and growth inhibition of k-ras-mutated cancer cells in vitro and in vivoTransl Res200815220321219010291
   PubMed Web of Science ®Google Scholar
• AppelsNMBeijnenJHSchellensJHDevelopment of farnesyl transferase inhibitors: a reviewOncologist20051056557816177281
   PubMed Web of Science ®Google Scholar
• BalkoJMJonesBRCoakleyVLBlackEPCombined MEK and EGFR inhibition demonstrates synergistic activity in EGFR-dependent NSCLCCancer Biol Ther2009852253019305165
   PubMed Web of Science ®Google Scholar
• MahoneyCLChoudhuryBDaviesHLKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signaling inhibitionBr J Cancer200910037037519165201
   PubMed Web of Science ®Google Scholar
• JacksonJRPatrickDRDarMMHuangPSTargeted anti-mitotic therapies: can we improve on tubulin agents?Nat Rev Cancer2007710711717251917
   PubMed Web of Science ®Google Scholar
• SchöffskiPPolo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncologyOncologist20091455957019474163
   PubMed Web of Science ®Google Scholar
• SteegmaierMHoffmannMBaumABI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivoCurr Biol20071731632217291758
   PubMed Web of Science ®Google Scholar
• VonPawelReckMDigelWRandomized phase II trial of two dosing schedules of BI 2536, a novel Plk-1 inhibitor, in patients with relapsed advanced or metastatic non-small cell lung cancer (NSCLC)J Clin Oncol200826Suppl abstract 8030
   Google Scholar
• RudolphDSteegmaierMHoffmannMBI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activityClin Cancer Res2009153094310219383823
   PubMed Web of Science ®Google Scholar
• GarlandLLTaylorCPilkingtonDLCohenJLVon HoffDDA phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1 interacting properties, in patients with advanced solid tumorsClin Cancer Res2006125182518916951237
   PubMed Web of Science ®Google Scholar
• OlmosDAllredASharmaRPhase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumorsJ Clin Oncol200927Suppl 15 abstract 3536
   Web of Science ®Google Scholar
• AdamsJPalombellaVJSauvilleEAProteasome inhibitors: a novel class of potent and effective antitumor agentsCancer Res1999592615262210363983
   PubMed Web of Science ®Google Scholar
• DaviesAMChanskyKLaraPNSouthwest Oncology Group. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S0339)J Thorac Oncol200941879219096312
   PubMed Web of Science ®Google Scholar
• LiTHoLPiperdiBPhase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)Lung Cancer201068899319524318
   PubMed Web of Science ®Google Scholar
• ButtsCMurrayNMaksymiukARandomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancerJ Clin Oncol2005236674668116170175
   PubMed Web of Science ®Google Scholar
• GridelliCRossiAMaionePVaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategyOncologist20094090992019726457
   PubMed Web of Science ®Google Scholar
• BunzFHwangPMTorranceCDisruption of p53 in human cancer cells alters the responses to therapeutic agentsJ Clin Invest199910426326910430607
   PubMed Web of Science ®Google Scholar
• RothJANguyenDLawrenceDDRetrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancerNat Med199629859918782455
   PubMed Web of Science ®Google Scholar
• NemunaitisJSwisherSGTimmonsTAdenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancerJ Clin Oncol20001860962210653876
   PubMed Web of Science ®Google Scholar
• SchulerMHerrmannRJacquesLPAdenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non–small-cell lung cancer: results of a multicenter phase II studyJ Clin Oncol2001191750175811251006
   PubMed Web of Science ®Google Scholar
• KatoHHaradaMIchinoseSPhotodynamic therapy (PDT) of lung cancer: experience of the Tokyo Medical UniversityPhotodiagnosis Photodyn Ther20041495525048064
   PubMed Web of Science ®Google Scholar
• SutedjaTGPostmusPEPhotodynamic therapy in lung cancer: a reviewJ Photochem Photobiol B1996361992049002261
   PubMed Web of Science ®Google Scholar
• JackmanDMJohnsonBESmall-cell lung cancerLancet20053661385139616226617
   PubMed Web of Science ®Google Scholar
• EliasAJIbrahimJSkarinATDose-intensive therapy for limited-stage small-cell lung cancer: long-term outcomeJ Clin Oncol1999171175118410561176
   PubMed Web of Science ®Google Scholar
• FetscherSBruggerWEngelhardtRStandard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up reportAnn Oncol19991056156710416006
   PubMed Web of Science ®Google Scholar
• KiuraKUeokaHTabataMPhase II study of high-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood stem cell transplantation for small-cell lung cancerProc Am Soc Clin Oncol200322632 (abstract 2540).
   Google Scholar
• StakerBLHjerrildKFeeseMDBehnkeCABurginABStewartLThe mechanism of topoisomerase I poisoning by a camptothecin analogProc Natl Acad Sci U S A200299153871539212426403
   PubMed Web of Science ®Google Scholar
• UeokaHOhnoshiTKimuraINew anthracycline analogues in the treatment of lung cancer (in Japanese)Gan To Kagaku Ryoho199219214621491332624
   PubMedGoogle Scholar
• SpigelDRHainsworthJDSimonsLIrinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research NetworkJ Thorac Oncol2007285486117805064
   PubMed Web of Science ®Google Scholar
• RudinCMKozloffMHoffmanPCPhase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancerJ Clin Oncol2004221110111715020613
   PubMed Web of Science ®Google Scholar
• HornLDahlbergSESandlerABPhase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501J Clin Oncol2009276006601119826110
   PubMed Web of Science ®Google Scholar
• MichaelMBabicBKhokhaRExpression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancerJ Clin Oncol1999171802180810561218
   PubMed Web of Science ®Google Scholar
• ShepherdFAGiacconeGSeymourLProspective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada – Clinical Trials Group and the European Organization for Research and Treatment of CancerJ Clin Oncol2002204434443912431965
   PubMed Web of Science ®Google Scholar
• RigasJRDenhamCARinaldiDAdjuvant targeted therapy in unresectable lung cancer: the results of two randomized placebo-controlled trials of BAY 12-9566, a matrix metalloproteinase inhibitor (MMPI)Lung Cancer200341Suppl 2S34 (abstract O107).
   Google Scholar
• ArnoldAMSeymourLSmylieMPhase II Study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada clinical trials group study BR.20J Clin Oncol2007254278428417878480
   PubMed Web of Science ®Google Scholar
• GiacconeGDebruyneCFelipEPhase III study of adjuvant vaccination with Bec2/bacille Calmette-Guérin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-09871B; Silva study)J Clin Oncol2005236854686416192577
   PubMed Web of Science ®Google Scholar
• DowlatiASubbiahSCooneyMPhase II trial of thalidomide asmaintenance therapy for extensive stage small cell lung cancer after response to chemotherapyLung Cancer20075637738117328989
   PubMed Web of Science ®Google Scholar